Perspective Therapeutics Income Statement (2010-2026) | CATX

1Y3Y5Y7Y10YAll
Download Data
Income Statement Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
2.71M2.56M2.82M2.91M2.50M1.72M1.83M1.50M2.19M-4.90M
Gross Profit (Quarter)
1.35M1.03M1.22M1.44M0.93M0.41M0.49M0.25M0.74M-0.04M
Operating items
Research & Development (Quarter)
0.70M0.54M0.55M0.80M0.71M0.47M3.31M5.37M5.55M7.08M7.45M9.28M12.03M12.88M14.33M16.62M20.34M32.92M21.37M
Selling, General & Administrative (Quarter)
1.84M1.62M1.58M1.58M3.11M4.85M6.66M4.99M4.47M4.94M5.88M5.51M6.97M8.25M7.84M7.71M7.73M6.95M6.99M
Other Operating Expenses (Quarter)
0.76M1.60M-5.31M-7.87M-0.30M-0.02M0.02M-0.03M
Operating Expenses (Quarter)
3.30M2.85M2.82M3.03M4.62M5.62M9.99M10.34M10.03M12.01M13.33M14.79M19.00M45.22M22.17M24.33M28.07M39.88M28.36M
Operating Income (Quarter)
1.35M-2.27M-1.64M-1.38M-2.11M-4.21M-5.62M-9.76M-9.75M-9.75M-11.68M-13.01M-14.26M-18.63M-44.98M-21.83M-24.04M-27.86M-39.83M-28.28M
EBIT (Quarter)
1.35M-2.27M-1.64M-1.38M-2.11M-4.21M-5.62M-9.76M-9.75M-9.75M-11.68M-13.01M-14.26M-18.63M-44.98M-21.83M-24.04M-27.86M-39.83M-28.28M
Non-operating items
Interest & Investment Income (Quarter)
0.03M0.03M0.03M0.03M0.14M0.56M0.37M0.29M0.20M0.06M1.21M3.08M3.58M2.65M2.38M2.16M1.96M1.61M2.20M
Other Non Operating Income (Quarter)
0.00M1.40M
Non Operating Income (Quarter)
0.03M0.03M0.03M0.03M0.14M0.56M0.36M0.27M0.18M0.03M1.18M3.05M3.51M2.72M3.65M2.04M1.89M1.55M2.09M
Net income details
EBT (Quarter)
1.35M-2.24M-1.60M-1.35M-2.08M-4.07M-7.33M-10.87M-11.11M-10.36M-7.77M-11.82M-11.21M-15.12M-41.83M-18.18M-22.00M-25.97M66.14M-26.19M
Tax Provisions (Quarter)
-10.50M10.50M
Profit After Tax (Quarter)
-1.06M-2.24M-1.60M-1.35M-2.08M-4.07M-7.33M-0.37M-11.11M-10.36M-24.68M-12.28M-11.70M-15.12M-40.17M-18.18M-21.48M-25.97M-37.49M-26.19M
Equity Income (Quarter)
-0.01M-0.01M-0.00M-0.00M-0.00M-0.00M-0.00M
Income from Continuing Operations (Quarter)
1.35M-2.24M-1.60M-1.35M-2.08M-4.07M-7.33M-0.37M-11.11M-10.36M-18.27M-11.82M-11.21M-15.12M-41.83M-18.18M-22.00M-25.97M66.14M-26.19M
Consolidated Net Income (Quarter)
1.35M-2.24M-1.60M-1.35M-2.08M-4.07M-2.27M-1.47M-1.62M-0.78M-5.18M-0.46M-0.49M0.51M-26.19M
Income towards Parent Company (Quarter)
1.35M-2.24M-1.60M-1.35M-2.08M-4.07M-2.27M-1.47M-1.62M-0.78M-5.18M-0.46M-0.49M0.51M-26.19M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-1.06M-2.24M-1.60M-1.35M-2.08M-4.07M-2.27M-1.47M-1.62M-0.78M-5.18M-0.46M-0.49M0.51M-26.19M
Additional items
EPS (Basic) (Quarter)
-0.01-0.02-0.01-0.01-0.01-0.03-0.04-0.01-0.34-0.34-0.57-0.24-0.17-0.21-0.61-0.25-0.30-0.35-0.51-0.25
EPS (Weighted Average and Diluted) (Quarter)
0.01-0.34-0.37-1.06-0.25-0.18-0.21-0.60-0.25-0.30-0.35-0.51-0.25
Shares Outstanding (Weighted Average) (Quarter)
2.65M141.91M141.96M142.04M141.99M142.07M0.26M228.59M28.00M26.32M0.58M49.51M58.08M70.63M0.42M72.36M73.30M74.30M73.81M103.60M
Shares Outstanding (Diluted Average) (Quarter)
228.59M28.00M28.05M26.76M49.51M58.08M70.63M64.42M72.36M73.30M74.30M73.81M103.60M
EBITDA (Quarter)
1.35M-2.27M-1.64M-1.38M-2.11M-4.21M-5.62M-9.76M-9.75M-9.75M-11.68M-13.01M-14.26M-18.63M-44.98M-21.83M-24.04M-27.86M-39.83M-28.28M
Interest Expenses (Quarter)
0.02M0.03M0.01M0.02M0.03M0.02M0.07M-0.07M0.13M0.12M0.07M0.06M0.10M
Shares Outstanding (Quarter)
141.92M141.92M142.04M142.04M142.04M142.11M14.21M27.87M28.05M28.06M28.18M58.69M67.43M67.56M70.67M74.05M74.26M74.34M74.34M114.02M
Tax Rate (Quarter)
96.59-135.08